Etifoxine Review Compared Rebound Anxiety With Benzodiazepine Comparators

Rebound after discontinuation is a separate endpoint from improvement during treatment.

What the supplied source reports

The narrative review discussed etifoxine’s GABA-related and neurosteroid mechanisms and comparisons with lorazepam, alprazolam and other agents in anxiety-related adjustment disorders. It reported less rebound anxiety after abrupt etifoxine cessation in certain comparisons and discussed psychomotor and memory outcomes.

Limits of the evidence

The review did not establish that every anxiety disorder or exposure duration has the same response. Etifoxine is not a benzodiazepine, and favorable results against a comparator do not create a universal equivalence or substitution rule. Narrative synthesis also does not eliminate limitations in the underlying trials.

Implications for expert analysis

For a withdrawal-related opinion, separate return of baseline symptoms, rebound beyond baseline and a broader withdrawal syndrome. Identify the original drug, duration and discontinuation pattern. The review supports attention to post-treatment observation rather than judging a regimen solely by symptom improvement while it is taken.

Source and related reading

Source: Publication PMC6615018, read from the supplied PDF. Applications to expert analysis are interpretation.